Pharming Group N.V. (PHGUF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 245.31 Million USD | 19.3% |
| 2022 | 205.62 Million USD | 8.31% |
| 2021 | 189.85 Million EUR | -16.88% |
| 2020 | 228.39 Million EUR | 20.63% |
| 2019 | 189.33 Million EUR | 22.49% |
| 2018 | 154.57 Million EUR | 43.77% |
| 2017 | 107.51 Million EUR | 544.06% |
| 2016 | 16.69 Million EUR | 41.01% |
| 2015 | 11.83 Million EUR | -54.05% |
| 2014 | 25.76 Million EUR | 172.6% |
| 2013 | 9.45 Million EUR | -32.67% |
| 2012 | 14.03 Million EUR | 261.1% |
| 2011 | 3.88 Million EUR | 410.06% |
| 2010 | 762.06 Thousand EUR | 58.77% |
| 2009 | 479.97 Thousand USD | -48.08% |
| 2008 | 924.35 Thousand EUR | -8.12% |
| 2007 | 1 Million EUR | 418.54% |
| 2006 | 194.01 Thousand USD | -59.55% |
| 2005 | 479.68 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 75.86 Million USD | 1.52% |
| 2024 Q2 | 73.72 Million USD | 33.42% |
| 2024 Q1 | 55.26 Million USD | -33.69% |
| 2023 FY | 245.31 Million USD | 19.3% |
| 2023 Q4 | 83.33 Million USD | 25.02% |
| 2023 Q1 | 42.54 Million USD | -22.12% |
| 2023 Q2 | 54.89 Million USD | 29.04% |
| 2023 Q3 | 66.66 Million USD | 21.43% |
| 2022 Q1 | 46.61 Million USD | -11.16% |
| 2022 Q2 | 50.14 Million USD | 7.57% |
| 2022 Q3 | 54.23 Million USD | 8.16% |
| 2022 Q4 | 54.62 Million USD | 0.71% |
| 2022 FY | 205.62 Million USD | 8.31% |
| 2021 Q3 | 51.93 Million EUR | 6.29% |
| 2021 Q2 | 48.86 Million EUR | 14.94% |
| 2021 Q1 | 42.5 Million EUR | -39.48% |
| 2021 Q4 | 52.47 Million EUR | 1.04% |
| 2021 FY | 189.85 Million EUR | -16.88% |
| 2020 FY | 228.39 Million EUR | 20.63% |
| 2020 Q4 | 70.23 Million EUR | 20.01% |
| 2020 Q1 | 54.36 Million EUR | 0.0% |
| 2020 Q2 | 45.26 Million EUR | -16.73% |
| 2020 Q3 | 58.52 Million EUR | 29.28% |
| 2019 Q2 | 49.05 Million EUR | 24.01% |
| 2019 FY | 189.33 Million EUR | 22.49% |
| 2019 Q4 | 54.36 Million EUR | 17.29% |
| 2019 Q3 | 46.35 Million EUR | -5.51% |
| 2019 Q1 | 39.55 Million EUR | -2.03% |
| 2018 Q4 | 40.37 Million EUR | -11.19% |
| 2018 Q2 | 32.39 Million EUR | -10.89% |
| 2018 FY | 154.57 Million EUR | 43.77% |
| 2018 Q3 | 45.45 Million EUR | 40.34% |
| 2018 Q1 | 36.34 Million EUR | -11.15% |
| 2017 Q2 | 18.53 Million EUR | 12.19% |
| 2017 Q1 | 16.52 Million EUR | 137.9% |
| 2017 Q3 | 31.55 Million EUR | 70.23% |
| 2017 FY | 107.51 Million EUR | 544.06% |
| 2017 Q4 | 40.9 Million EUR | 29.66% |
| 2016 Q1 | 2.5 Million EUR | 9.47% |
| 2016 FY | 16.69 Million EUR | 41.01% |
| 2016 Q4 | 6.94 Million EUR | 78.86% |
| 2016 Q3 | 3.88 Million EUR | 15.65% |
| 2016 Q2 | 3.35 Million EUR | 33.8% |
| 2015 Q1 | 1.92 Million EUR | -90.77% |
| 2015 FY | 11.83 Million EUR | -54.05% |
| 2015 Q4 | 2.29 Million EUR | -37.62% |
| 2015 Q3 | 3.67 Million EUR | -6.83% |
| 2015 Q2 | 3.94 Million EUR | 104.61% |
| 2014 Q3 | 1.41 Million EUR | -6.6% |
| 2014 Q4 | 20.88 Million EUR | 1378.69% |
| 2014 FY | 25.76 Million EUR | 172.6% |
| 2014 Q1 | 1.95 Million EUR | 39.52% |
| 2014 Q2 | 1.51 Million EUR | -22.51% |
| 2013 Q3 | 1.67 Million EUR | -71.01% |
| 2013 Q4 | 1.39 Million EUR | -16.26% |
| 2013 FY | 9.45 Million EUR | -32.67% |
| 2013 Q1 | 619.81 Thousand EUR | -94.44% |
| 2013 Q2 | 5.76 Million EUR | 829.57% |
| 2012 Q2 | 1.06 Million EUR | -9.11% |
| 2012 Q3 | 653.26 Thousand EUR | -38.63% |
| 2012 FY | 14.03 Million EUR | 261.1% |
| 2012 Q4 | 11.14 Million EUR | 1606.3% |
| 2012 Q1 | 1.17 Million EUR | 20.8% |
| 2011 Q2 | 999.96 Thousand EUR | 11.36% |
| 2011 Q1 | 897.97 Thousand EUR | 694.64% |
| 2011 Q3 | 1.01 Million EUR | 1.95% |
| 2011 Q4 | 969.61 Thousand EUR | -4.89% |
| 2011 FY | 3.88 Million EUR | 410.06% |
| 2010 Q4 | -151.01 Thousand EUR | -141.81% |
| 2010 Q3 | 361.14 Thousand EUR | 67.51% |
| 2010 Q2 | 215.59 Thousand EUR | 0.0% |
| 2010 FY | 762.06 Thousand EUR | 58.77% |
| 2010 Q1 | - USD | -100.0% |
| 2009 FY | 479.97 Thousand USD | -48.08% |
| 2009 Q4 | 792.72 Thousand EUR | 195.82% |
| 2009 Q3 | 267.97 Thousand EUR | -23.49% |
| 2009 Q1 | 137.97 Thousand EUR | 0.0% |
| 2009 Q2 | 350.26 Thousand EUR | 153.86% |
| 2008 FY | 924.35 Thousand EUR | -8.12% |
| 2007 FY | 1 Million EUR | 418.54% |
| 2006 FY | 194.01 Thousand USD | -59.55% |
| 2005 FY | 479.68 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -323860.699% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -1246.558% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -99.519% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -12597.516% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -1455.291% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -1392079.785% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -1042.173% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -373129.065% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -4056.489% |
| Marizyme, Inc. | 645.81 Thousand USD | -37885.785% |
| Genus plc | 668.8 Million USD | 63.32% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -247708.958% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -59709.101% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -319484.164% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -620670.282% |
| MultiCell Technologies, Inc. | 49.32 USD | -497396493.674% |
| ONE Bio Corp. | 52.29 Million USD | -369.09% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -393.385% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -501568.712% |
| Q BioMed Inc. | 284.35 Thousand USD | -86171.945% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -728.854% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -69.067% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -43886.301% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -350351.429% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -37153.759% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 98.33% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -24556056.156% |
| Enzolytics Inc. | 52.79 Thousand USD | -464548.837% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -40213.216% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 79.996% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -174823.347% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -39634.752% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 70.779% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -24487.512% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -407.333% |
| BioStem Technologies, Inc. | 16.68 Million USD | -1370.243% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -103601.387% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -103601.387% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -17819.357% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -51683.928% |
| SYBLEU INC | 11.69 Thousand USD | -2097335.021% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -3049.519% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1886946.154% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -620419.047% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -7266.847% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -3580.66% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -23510.78% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -852.055% |
| CSL Limited | 14.8 Billion USD | 98.342% |
| Cellectis S.A. | 755 Thousand USD | -32392.185% |